🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Aggression

Regulating Together for Intellectual Disability and Autism: A Group Behavioral Therapy for for Emotion Dysregulation NCT07624448NA1 site📍 Kansas City Children's Mercy Hospital Kansas City · Tests: Regulating Together group therapy Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049Phase 1, Phase 23 sites📍 Minneapolis📍 Columbus📍 Richmond Yazeed Sawalha · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab Transgender Men, Non-binary Persons and Testosterone Treatment BODY IDENTITY CLINIC NCT04254354n/a1 site📍 Odense Marianne Andersen Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL NCT06806033Phase 253 sites📍 Anchorage📍 Clovis📍 Fullerton Hoffmann-La Roche · Tests: Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin Single-cell and Spatial Transcriptomic Profiling of Gingival Tissues in Aggressive and Chronic Periodontitis: Deciphering Cellular Heterogeneity and Inflammatory Microenvironment Features NCT07487272n/a1 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism NCT07091279Phase 22 sites📍 Staten Island📍 White Plains Jeremy Veenstra-vanderweele · Tests: Propranolol, Placebo Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma NCT06649812Phase 2114 sites📍 Tucson📍 Tucson📍 Los Angeles National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Role of MRI Assessment in Fertility Sparing Treatment for Cervical Cancer at Staging and Follow-up and for Identification of Risk Factors for Aggressive Disease. NCT06877065n/a1 site📍 Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas NCT05685173Phase 120 sites📍 Duarte📍 Santa Monica📍 Louisville Regeneron Pharmaceuticals · Tests: Odronextamab, REGN5837 Regulating Together for Prader-Willi Syndrome: A Group Behavioral Therapy for Emotion Dysregulation NCT07607730NA1 site📍 Kansas City Children's Mercy Hospital Kansas City · Tests: Regulating Together group therapy A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) NCT06173518Phase 114 sites📍 Los Angeles📍 Palo Alto📍 Aurora Autolus Limited · Tests: AUTO1 Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas NCT07883135Phase 21 site📍 Moscow National Research Center for Hematology, Russia · Tests: Glofitamab, Epcoritamab, Polatuzumab Vedotin, Gemcitabine & oxaliplatin, Obinutuzumab Butyrophilins Role in Colon Cancer NCT04185272NA1 site📍 Marseille Institut Paoli-Calmettes · Tests: analysis of BTN and BTNL status Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma NCT06996132Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Glofitamab, Chimeric Antigen Receptor T Cells (CAR-T) Actinium Therapy for Late-stage Aggressive Sarcomas NCT07156565Phase 16 sites📍 Los Angeles📍 Rochester📍 New York Ratio Therapeutics, Inc. · Tests: [Ac 225]RTX-2358, [Cu64]LNTH-1363S A Virtual Reality Mindfulness Application for Aggression in Schizophrenia NCT07434479NA2 sites📍 New York📍 White Plains Manhattan Psychiatric Center · Tests: Mindfulness-Based Virtual Reality Intervention Short-Stay Aggressive Hydration to Prevent Post-ERCP Pancreatitis NCT07776561NA1 site📍 Westmead Westmead Hospital · Tests: Short-Stay Aggressive Hydration, Standard Peri-procedural Hydration, Rectal Indomethacin CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). NCT05260957Phase 21 site📍 Miami Lazaros Lekakis · Tests: Mosunetuzumab, Polatuzumab, CAR-T Cell Therapy Efficacy of a Multi-level School Intervention for LGBTQ Youth NCT05541406NA23 sites📍 El Monte📍 El Monte📍 El Monte Washington University School of Medicine · Tests: Proud & Empowered, Control Group Aggressive Smoking Cessation Trial (ASAP) NCT05257629Phase 313 sites📍 New Westminster📍 Moncton📍 St. John's Sir Mortimer B. Davis - Jewish General Hospital · Tests: Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling), Varenicline Plus Counseling Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer NCT06738303Phase 21 site📍 Cleveland Case Comprehensive Cancer Center · Tests: Cabazitaxel and carboplatin, Lu-PSMA-617 Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) NCT05563558Phase 21 site📍 Madrid Fundacion Oncosur · Tests: Pembrolizumab, Carboplatin, Cabazitaxel Momentary Coping Prompts and Hair Steroids in College Students NCT07782398NA1 site📍 Gainesville University of Florida · Tests: Momentary coping prompt, Active control message Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial NCT04948749NA18 sites📍 Beijing📍 Beijing📍 Cangzhou Beijing Tiantan Hospital · Tests: Drug Eluting Stent implantation, Aggressive medical treatment, Risk factor management, Standard medical treatment MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) NCT06534437Phase 235 sites📍 Le Mans📍 Lille📍 Limoges Ryvu Therapeutics SA · Tests: MEN1703, Glofitamab Trauma-Informed Peer Aggression and Dating Violence Prevention for Preteens Receiving Intensive Mental Health Services NCT06769282NA1 site📍 Providence Rhode Island Hospital · Tests: Experimental: Intervention (SPARE) plus Treatment as Usual, Treatment as Usual (TAU) Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma NCT05077527Phase 17 sites📍 Duarte📍 Chicago📍 New York AIDS Malignancy Consortium · Tests: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine B Cell Functions in Periodontitis NCT02833285n/a1 site📍 Brest University Hospital, Brest Flourish in Schools Pilot Study NCT07506525NA2 sites📍 Bay Village📍 Pittsburgh Candice Biernesser · Tests: Flourish Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) NCT07179783Phase 21 site📍 Tianjin Tianjin Medical University Second Hospital · Tests: Sacituzumab Tirumotecan, Tagitanlimab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy